Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

Plant lectins as prospective antiviral biomolecules in the search for COVID-19 eradication strategies

Md. Nasir Ahmed a,b,*, Rownak Jahan a,**, Veeranoot Nissapatorn c, Polrat Wilairatana d,**, Mohammed Rahmatullah a,***

a Department of Biotechnology & Genetic Engineering, University of Development Alternative, Dhaka, Bangladesh
b Biotechnology & Natural Medicine Division, TechB Nutrigenomics, Dhaka, Bangladesh
c School of Allied Health Sciences and World Union for Herbal Drug Discovery (WUHeDD), Wallace University, Nakhon Si Thammarat, Thailand
d Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

A R T I C L E   I N F O

Keywords:
Mannose-specific/mannose-binding lectins
Glycoprotein
Glycosylation
SARS-CoV-2 glycobiology
Antiviral plant lectins
Glycobiochemistry

A B S T R A C T

Lectins or clusters of carbohydrate-binding proteins of non-immune origin are distributed chiefly in the Plantae. Lectins have potent anti-infectivity properties for several RNA viruses including SARS-CoV-2. The primary purpose of this review is to review the ability of lectins mediated potential biotherapeutic and bioprophylactic strategy against coronavirus causing COVID-19. Lectins have binding affinity to the glycans of SARS-COV-2 Spike glycoprotein that has N-glycosylation sites. Apart from this, the complement lectin pathway is a “first line host defense” against the viral infection that is activated by mannose-binding lectins. Mannose-binding lectins deficiency in serum influences innate immunity of the host and facilitates infectious diseases including COVID-19. Our accumulated evidence obtained from scientific databases particularly PubMed and Google Scholar databases indicate that mannose-specific/mannose-binding lectins (MBL) have potent efficacies like anti-infectivity, complement cascade induction, immunoadjuvants, DC-SIGN antagonists, or glycomimetic approach, which can prove useful in the strategy of COVID-19 combat along with the glycobiological aspects of SARS-CoV-2 infections and antiviral immunity. For example, plant-derived mannose-specific lectins BanLac, FRIL, Lentil, and GRFT in-vitro, in-vivo, and in-silico assessments. Furthermore, Bangladesh has a noteworthy resource of antiviral medicinal plants as well as plant lectins. Intensifying research on the antiviral plant lectins, adopting a glyco-biotechnological approach, and with deeper insights into the “glycovirological” aspects may result in the designing of alternative and potent blueprints against the 21st century’s biological pandemic of SARS-CoV-2 causing COVID-19.

1. Introduction

Lectins are a diverse group of carbohydrate-binding natural proteins that bind reversibly to mono and oligosaccharides with high specificity [1]. The first study of lectin began more than 130 years ago in 1888 by Peter Hermann Stillmark with the finding that the seed extracts of Castor bean can agglutinate red blood cells and the isolated lectin was named Ricin [2]. During World War I and II ricin was utilized as a potential weapon by the United States and British military, respectively [3]. The modern age of lectinology began in 1972 with the purification of lectins from different plant sources [4]. Seeds, tubers, leaves, stems, roots, and fruits of medicinal plants are rich sources to isolate and purify lectins [5], specially from the Leguminosae family [6], and large numbers of lectins are present in seed cotyledons [7]. Lectins can target the sugar complex of glycoproteins and all the lectins possess two or more carbohydrate-binding sites with the essential property of agglutinating ability to the erythrocytes without altering the carbohydrates properties [8]. Lectins can be classified based on binding

Abbreviations: GEP, glycosylated envelope proteins; MBPL, mannose-binding plant lectin; MBL, mannose-binding lectin; sMBL, serum MBL; MASP, (MBL)-associated serine proteases; pdMBL, plasma-derived human mannose-binding lectin.

* Corresponding author at: Department of Biotechnology & Genetic Engineering, University of Development Alternative, Dhaka, Bangladesh.
** Corresponding authors.

E-mail addresses: nasir.ahmedbd@hotmail.com (Md.N. Ahmed), rownak86@hotmail.com (R. Jahan), polrat.wil@mahidol.ac.th (P. Wilairatana), rahamattm@hotmail.com (M. Rahmatullah).

https://doi.org/10.1016/j.biopha.2021.112507
Received 20 October 2021; Received in revised form 2 December 2021; Accepted 3 December 2021
Available online 7 December 2021
0753-3322/© 2021 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
specificity as glucose/mannose, galactose and N-acetyl-D-galactosamine, N-acetylglucosamine, L-fucose, and sialic acids [9]. Lectins may also be categorized into merolectins, hololectins, chimerolectins, and superlectins based on the number of binding sites [9]. Plant lectins can be classified into 12 families based on species and lectin domain [10]. Man-specific or mannose-specific lectins have specificity for mannose and mannose containing glycoproteins and they are widely present in all living organisms, and especially have been isolated and identified from plants, algae, fungi, and cyanobacteria [11].

The application of lectins is dependent on their properties, and some of the lectins derived from the natural resources have in-vivo and in-vitro antiviral activities [12]; therefore, some of these novel lectins have been considered for the potential development of therapeutic agents against viral infections [12]. Lectins are highly potent in virus neutralization activities and their modes of action can target enveloped viruses that share the feature of glycosylated proteins on their surfaces [13]. Thus, lectins can inhibit the replication of viruses by interacting with viral envelope proteins. Such antiviral lectins have extensively been evaluated in-vitro for their neutralization effects on different enveloped viruses including coronaviruses and HIV [13], because lectins can interfere with the virus entry and inhibit the viral proteins production [14]. Lectins have also been used as glyco-analytical tools in the development of biosensors for the diagnosis of infectious diseases and detection of viral pathogens [15]. Example includes, Concanavalin A (ConA) lectin can recognize the structural glycoproteins of the arboviruses [16]. In another study, five lectins such as Dolichos biflorus lectin (DBA), Helix pomatia lectin (HPA), peanut lectin (PNA), soybean lectin (SBA), and Ulex europaeus lectin (UEA-1) were evaluated for the detection of hepatitis A virus (HAV) and amongst the five lectins, SBA showed significant activity in the detection of HAV [17].

In addition, some lectins may have mitogenic activity that leads to systemic inflammation [18], and increase viral transmission because of their ability to activate T cells [19]. Lectin-induced mitogenicity can be overcome by attempting glycoengineering techniques such as BanLac, which was engineered to eliminate its mitogenicity by amino acid mutation at position 83–84 from histidine to threonine [19], without compromising antiviral activity against Ebola and influenza viruses [20, 21]. In another recent study published in April 2021, a site-specific engineered lectin based on structural insights, Pseudomonas taiwanensis lectin (PTL), reportedly enhanced antiviral activity against the influenza virus and such site-specific engineering of lectins can be a potential strategy to boost the antiviral activity of lectins [22]. The data from 2015 to 2020 showed that numerous potential antiviral lectins were discovered along with studies of structural modifications when needed [23].

1.1. Antiviral plant lectins and their modes of action

The contribution of plant lectins as antiviral activity was first reported in 1988 wherein D-mannose-specific plant lectins blocked the binding of HIV in-vitro [24]. Glycosylated envelope proteins (GEP) are a particular protein for the regulation of virus recognition and virus entry. They exert affinity for cell-surface proteins of host cells, and therefore the antiviral lectins react with the high-mannose glycan to trigger glycosylation of viral GEP [12]. A glycosylated envelope protein complex of HIV has transmembrane trimer, gp31 and extracellular trimer, gp120 that contain N-linked oligosaccharide attachment sites. These structures assist viral evasion of the host immune system and entry into

![Fig. 1. “Schematic representation of viral infection (A) and the role of cyanobacterial lectin, cyanovirin (CV-N) on inhibition of viral entry and fusion (B). CV-N blocks the interaction between the viral gp120 and the CD4 receptor on the host cell. It prevents the interaction with the associated co-receptors CXCR4/CCR5. As a consequence, the virus cannot enter into the cell.” Adapted from [27] distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.](image-url)
the host cells, mediated by recognition of CD4+ triggering. The antiviral lectins inhibit the conformational reorganization of the glycosylated envelope protein complex and thus result in suppressing virus entry into host cells [12,25]. Specific carbohydrate-binding lectins are considered as potential anti-HIV agents which can block the host-virus interactions at their earliest stage because of the glycosylated action of the viral envelope proteins [26]. The following figure, Fig. 1, represents the role of cyanobacterial lectin against viral infection.

Since antiviral medicinal plants and their bioactive compounds are potential sources that may play a significant role in the development of COVID-19 biotherapeutics [28–31], we documented some plant lectins from reported antiviral medicinal plants available in Bangladesh in Table 1.

The in-vitro antiviral potency of bioactive compounds or drugs can be determined by the two most commonly reported parameters such as EC50 (EC for effective concentration), the concentration of bioactive compounds (drugs) in cell culture media that provides 50% maximal protection against virus induced cytopathicity and IC50 (IC for inhibitory concentration), the concentration of bioactive compounds (drugs) that yields 50% of the maximum inhibitory effect.

In a study of antiviral activity, Gondim and coauthors have evaluated 4 leguminous lectins, namely Canavalia brasiliensis (ConBr), C. martima (ConM), Dioclea lasiocarpa (DLasl) and D. scirchora (DSclerL), and 5 algal lectins: Amanzia multifida (AML), Bryophyllum seaforthish (BSL), Hypnea musciformis (HML), Merisistella echinocarpa (MEL) and Soleria filiformis (SFL) from the Brazilian biodiversity, which are active against 18 different viruses, including influenza viruses and HIV. On the basis of EC50 values, the most potential lectins were DLasl and DSclerL, which showed EC50 values ranging from 9 nM to 46 nM for HIV-1 and respiratory syncytial virus, respectively; DSclerL, ConBr and ConM showed EC50 ranging from 0.4 to 6 nM against influenza A virus strain H3N2 and influenza B virus, and DLasl showed EC50 of 5 nM against feline coronavirus [128]. In a review study published in August 2021, Carneiro and co-authors have demonstrated antimicrobial applications of patented lectins and listed some patented lectins that exhibited in-vitro antiviral activity [129] (see Table 2).

2. Potentials of lectins against SARS-CoV-2 infectivity

Lectins can be used to identify and characterize the structure of glycans [130]. Glycans are the carbohydrate portion of glycoproteins which have crucial roles in the immune system of humans [131] and pathobiology of viral infections [132]. Antiviral lectins can block the entry of virus by binding to glycans from either the virus or host cell [129]. Antiviral lectins can bind to the viral Spike (S) protein of SARS-CoV [116]; specifically, lectins like mannose/gluucose and N-acetylgalactosamine (GlCNAC)- specific lectins have been found to inhibit entry of several coronaviruses such as SARS-CoV [133,134], MERS-CoV [135], and other coronaviruses [136,137].

The glucose/mannose-specific plant lectin FRIL, derived from Lablab purpureus, is effective both in vivo and in vitro for neutralizing SARS-CoV-2 binding to complex-type-N-glycans on viral glycoproteins [138]. Another plant lectin which is mannose-specific, lentil, isolated from Lens culinaris, showed strong inhibitory SARS-CoV-2 activity at the early steps of infections by blocking the ACE2-S trimmer binding to oligomannose-type glycans and N-acetylgalactosamine at glycosylation sites N165, N234, and N343, which are located around the receptor binding domain [139].

The algal lectin, GRFT (Griffithsin), derived from red alga Geitrihisia sp., is a high mannose-specific lectin, which significantly inhibits SARS-CoV-2 pseudovirus infection in vitro with an IC50 of 63 nM/L compared to remdesivir with effective concentration of 0.77 μM/L; GRFT also inhibits SARS-CoV-2 S-mediated cell to cell fusion with an IC50 of 323 nmol/L [140]. GRFT has also been reported to inhibit SARS-CoV infectivity in previous in vivo and in vitro studies [133]. The following table, Table 3, lists some algae-derived mannose-specific antiviral lectins that have been reported to be potent inhibitors of different RNA viruses summarized by Alam et al. [141], and can be potent inhibitors of coronaviruses as well.

From molecular docking and MD simulation studies, Banana derived mannose-specific lectin, BanLec, can target N-glycans of the Spike glycoproteins to neutralize SARS-CoV-2 infectivity [142]. The following table, Table 4, is listed with some antiviral plant lectins, which are reportedly potent inhibitor of coronaviruses by targeting both the early virus replication cycle and the end of the infectious virus cycle (modified from Bah et al. [143]).

The antiviral medicinal plant Withania somnifera (L.) Dunal, which is called Indian ginseng has potential for COVID-19 management [127]. An in-silico docking and molecular dynamics results have showed its (phytochemicals of W. somnifera) ability to inhibit SARS-CoV-2 host entry and replication [144], and the plant has effective roles on the host ACE2 receptor complex and receptor binding domain (RBD) of virus [145]. It is worth noting that a mannose-specific lectin was isolated from leaves of W. somnifera [125].

2.1. Lectin mediated DC-SIGN antagonists and glycomimetic approach

C-type lectins, which according to their property of Ca2+ dependent carbohydrate-binding lectins, were identified as the key susceptibility factors that interact with multiple viruses, and then induce infection [146]. DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin) is such a mannose-specific C-type lectin and pathogen recognition receptor of human innate immune system expressed in dendritic cells [147]. DC-SIGN can recognize N-linked high-mannose oligosaccharides and branched fucosylated structures [148]. It has been reported that DC-SIGN can act as an alternative receptor for SARS-CoV-2 entry, therefore enhancing infectivity [149,150]. The glycomimetic antagonists of DC-SIGN and L-SIGN which is another C-type lectin, highly expressed in human type II alveolar cells and the endothelial cells of the lung, liver, and lymph nodes can be promising candidates for the inhibition of SARS-CoV-2 entry to host cell receptors [150]. Therefore, DC-SIGN antagonist that act as a glycomimetic approach, are potential anti-infectives [151], and several glycomimetics are already in clinical trials [152]. In-vitro assays have confirmed ability of the plasma-derived human mannose-binding lectin to block binding of SARS-CoV to DC-SIGN [153]. Furthermore, the algal lectin GRFT and cyanobacterial lectins Cyanovirin-N, and Sctovirin can block HIV-1 binding to the DC-SIGN receptor and the DC-SIGN-mediated HIV-1 infection of CD4(+) cells [154].

2.2. Mannose-binding lectins and SARS-CoV-2 possible interactions

The SARS-CoV-2 Spike (S) glycoprotein has S1 and S2 subunits linked through transmembrane protease serine 2 (TMPRSS2) and furin cleavage sites [155]. The S1 subunit is involved in the attachment to host cell receptors facilitated by a receptor binding domain (RBD), and S2 is involved in the fusion of cellular membranes in between virus and human [155]. The entry of SARS-CoV-2 into human host cells is shown schematically in Fig. 2.

Watanabe et al. [157] and Zhou et al. [158] has identified the location of 22 N-linked highly glycosylated sites where glycans are attached to the SARS-CoV-2 Spike glycoproteins and the types of sugar at each site. High mannose-type glycans were identified on the site N234 of the S glycoprotein of SARS-CoV-2, and Complex-type N-glycans and high mannose-type glycans were identified at the sites N165, N331, and N343 [155]. The SARS-CoV-2 Spike proteins are coated with sugars (glycans) [158]; neutralization of the sugar-coated Spike protein by using lectins, which behaves as sugar-binding proteins, can be a promising strategy for the COVID-19 therapeutics. For instance, the two mannose-specific mammalian lectins (Clec4g and CD209c) strongly bind to the N-glycan site N343 of the SARS-CoV-2 Spike protein, which can be visualized and quantified using atomic force microscopy [159].
| Botanical name                        | Family                | Used plant part | Lectin identification, isolation and purification (reference) | Specificity                                      | Antiviral activity (reference) |
|--------------------------------------|------------------------|-----------------|---------------------------------------------------------------|-------------------------------------------------|-------------------------------|
| Abelmoschus esculentus (L.) Moench  | Malvaceae              | Seed            | [32]                                                          | Non-specified                                   | Not reported                  |
| Abru praeatorium (L.) Corea          | Fabaceae               | Seed            | [33]                                                          | Galactose                                       | Coronavirus[34]               |
| Ange marmolos (L.) Correa            | Rutaceae               | Fruit pulp      | [35]                                                          | N-acetylglactosamine, Mannose and sialic acid  | Coxsackie viruses B1–B6, BmNPV[36,37] |
| Aliina plantago-aquatica var. orientale Lam. | Alismataceae       | Rhi zone        | [38]                                                          | Non-specified                                   | HBV, HSV[1,39,40]             |
| Amananthus viridis L.                | Amaranthaceae          | Seed            | [41]                                                          | T-antigen and N-acetyl-D-lactosamine            | Measles virus[42]             |
| Areca catechu L.                     | Areicaceae             | Nut             | [43]                                                          | Non-specified                                   | HIV-1, NDV[44,45]             |
| Aricarpos heterophylla Lam.          | Moraceae               | Seed            | [46]                                                          | Galactose and N-acetylglactosamine              | HIV, HSV-2, CMV, HCV          |
| Bauhinia variegata L.                | Fabaceae               | Seed            | [50]                                                          | Glucose/Galactose                               | Coxsackievirus B3, Rotavirus  |
| Benincasa hispida (Thunb.) Cogn.     | Cucurbitaceae          | Fruit           | [53]                                                          | N-acetylglucosamine                             | Not reported                  |
| Butea monosperma (Lam.) Taub         | Leguminosae            | Seed            | [54,55]                                                       | N-acetylglactosamine, N-acetyl d-               | Unknown[56]                   |
| Caju nas cajan (L.) Millsp.          | Fabaceae               | Root            | [57]                                                          | Galactose                                       | Measles virus[58]             |
| Cassia fistula L.                    | Fabaceae               | Seed            | [59]                                                          | Mannose/glucose                                 | IBR[60]                      |
| Citrus unshiu L.                     | Rutaceae               | Seed            | [61]                                                          | Galactose and N-acetylglactosime               | MCV, HSV[62]                  |
| Coccinia indica Wight & Arn.         | Cucurbitaceae          | Fruit           | [63]                                                          | Chito                                           | HBV[64]                      |
| Corchorus olitorius L.               | Tiliaceae              | Leaf            | [65]                                                          | Glucose/mannose, galactose                      | Measles virus[66]             |
| Cucurbita maxima Duchene             | Cucurbitaceae          | Seed            | [67]                                                          | Galactose                                       | Not reported                  |
| Datura stramonium L.                 | Solanaceae             | Seed            | [68]                                                          | N-Acetylglucosamine                             | Potato virus X[69]            |
| Erythrina variegate L.               | Fabaceae               | Seed            | [70,71]                                                       | Galactose, N-acetylglactosamine                 | Not reported                  |
| Glycyrrhiza glabra L.                | Fabaceae               | Root            | [72]                                                          | Non-specified                                   | HAV, HBV, HCV, HIV, SARS-CoV[73,74] |
| Kaempferia rotunda L.                | Zingiberaceae          | Rhi zone        | [75]                                                          | Mannose                                         | HSV[76]                      |
| Kaempferia parviflora Wall. ex Baker | Zingiberaceae          | Rhi zone        | [77]                                                          | Non-specified                                   | HIV-1, HCV, HCMV[78]         |
| Lathyrus sativus L.                  | Fabaceae               | Seed            | [79]                                                          | Mannose                                         | Not reported                  |
| Litchi chinensis Sonn.               | Sapindaceae            | Seed            | [80]                                                          | Glucose/mannose                                 | HSV-1[81]                    |
| Mangifera indica L.                  | Anacardaceae           | Fruit seed      | [82]                                                          | Non-specified                                   | HSV, influenza virus[83,84]   |
| Momordica charantia L.               | Cucurbitaceae          | Seed            | [85]                                                          | Galactose/- N-Acetylglactosamine                | HSV, HSV-1, H1N1, H3N2,      |
| Mucuna pruriens (L.) DC.             | Fabaceae               | Seed            | [89]                                                          | Mannose                                         | HSV[85]                      |
| Musa paradisiaca L.                  | Musaceae               | Ripe fruit pulp | [91]                                                          | Mannose                                         | HSV-1, HSV-2[91]              |
| Oryza sativa L.                      | Poaceae                | –               | [82]                                                          | N-Acetylglucosamine                             | CMV, HSV[92,93]               |
| Phaseolus vulgaris L.                | Fabaceae               | Seed            | [94,95]                                                       | Galactose                                       | HIV-1 RT[94,95]               |
| Psidium guajava L.                   | Myrtaceae              | Fruit           | [96]                                                          | Mannose                                         | H1N1[97]                     |
| Pau am sativum L.                    | Fabaceae               | Seed            | [82,98]                                                       | Galactose/mannose                               | HSV-1, ADV[98,99]            |
| Pericarpus indicus Willd             | Fabaceae               | Seed            | [100]                                                         | Mannose/glucose                                 | Dengue virus[101]             |
| Senna tora (L.) Roxb.                | Fabaceae               | Seed            | [102]                                                         | Mannose/Galactose                               | SARS-CoV[3CL protease][103]   |
| Senna occidentalis (L) Link          | Fabaceae               | Seed            | [104]                                                         | Non-specified                                   | BHV-1, SHV-1[1105]           |
| Schisandra bignosus (Jacq.) W.Wight   | Fabaceae               | Stem            | [106]                                                         | Glucose                                         | Not reported                  |
| Solanum lycopersicum L.              | Solanaceae             | Fruit           | [107]                                                         | N-acetylglucosamine                             | Not reported                  |
| Solanum melongena L.                 | Solanaceae             | Fruit           | [108]                                                         | Non-specified                                   | HSV-1[109]                   |
| Tamarindus indica L.                 | Fabaceae               | Seed            | [110]                                                         | Mannose/maltose                                 | NDV, mosaic viruses[111,112]  |
| Trichosanthes cucumcima L.           | Cucurbitaceae          | Seed            | [113]                                                         | Galactose                                       | Not reported                  |
| Trichosanthes dioica Roxb.           | Cucurbitaceae          | Seed            | [114]                                                         | Galactose and N-acetylglactosamine              | Not reported                  |
| Utica dioica L.                      | Uricaceae              | Root            | [115]                                                         | N-acetylglucosamine                             | SARS-CoV; HIV, CMV, RSV, H1N1[12,116,117] |
| Vigna mungo (L.) Hepper               | Fabaceae               | Seed            | [118]                                                         | Galactose                                       | Urbane Leaf Crinkle Virus[119]|
| Vigna radiata (L) R. Wilczek          | Fabaceae               | Seed            | [120]                                                         | Galactose                                       | Influenza A virus, HSV-1, RSV |
| Vigna unguiculata (L) Wald           | Fabaceae               | Seed            | [123]                                                         | Non-specified                                   | HIV[124]                     |
| Withania somnifera (L) Dunal          | Solanaceae             | Leaf            | [125]                                                         | Mannose                                         | SARS-CoV-2, HIV, HSV, H1N1[126,127] |

HSV = Herpes simplex virus; HAV = Hepatitis A virus; HBV = Hepatitis B virus; HCV = Hepatitis C virus; CMV = Cytomegalovirus; RSV = Respiratory Syncytial Virus; ADV = Adenoviruses; MCV = Molluscum contagiosum virus; BmNPV = Bombmy mori nucleopolyhedrovirus; IBR = Infectious Bovine Rhinotracheitis; HIV = Human immunodeficiency viruses; H1N1, H3N2, H5N1 = Subtypes of Influenza A virus; NDV = Newcastle disease virus; BHV = Bovine herpesvirus-1; SHV = swine herpesvirus 1.
High mannose-specific seaweed lectins have the ability to interfere with both the virus entry in the host cell and virus release from the host cell by targeting the Spike glycoprotein and heavily glycosylated ACE2 receptor [160]. ACE2 stands for Angiotensin converting enzyme 2, and is expressed in human organs and play a chief role in the entry of SARS-CoV-2 [161] by binding of S1 subunit to ACE2 receptors [162] (see Fig. 2 as well) and the molecular mechanisms of SARS-CoV-2 binding to the ACE2 receptor has been discussed by Ramírez Hernández et al. [163].

An in-vitro study [153] showed that plasma-derived human mannose-binding lectin (pMBL) selectively binds to SARS Spike (SARS-S) glycoprotein and can inhibit SARS-CoV infection in susceptible cell lines. This experiment has identified a single N-glycosylation site, N330, on S glycoprotein as the target for the specific interactions between pMBL and SARS-CoV. Comparably, Mannose-binding plant lectins (MBPLs) can interfere during virus entry by binding to the high-mannose type N-glycans of SARS-CoV Spike (S) protein, and by blocking viral attachment to the host cell [116,164] wherein N-linked glycosylation plays a critical role in the specific interaction between the MBPLs and SARS-CoV Spike glycoprotein [165].

It is worth noting that the lower levels of serum mannose-binding lectin (sMBL) in human blood is associated with the occurrence of many infectious diseases including SARS, as MBL has a pivotal role in innate immune response [166,167]. Mannose-binding lectin deficiency (< 70 ng/ml) in serum has been reported in 25 patients with viral upper respiratory infections and in 13 patients with immunodeficiencies [168]. A case report study of a 2-times COVID-19 affected patient showed MBL deficiency (< 50 ng/ml), which indicated that patients with decreased levels of MBL may have greater risk of COVID-19 re-infection than the general people [169]. Serum MBL levels test in COVID-19 patients should be carried out (by using a sample of the patient’s blood and Enzyme-linked immunosorbent assay) to avoid critical conditions and targeting the mannose-binding pathway (see Fig. 3) can be a potential treatment for COVID-19 as well for thrombosis in COVID-19 [170]. Changes in the MBL2 gene can lead to MBL (produced in the liver) deficiency that is very common in the general population and reduced MBL levels in blood serum (< 500 ng/ml) may be considered as susceptibility for recurrent infection including respiratory tract infections by pathogens as well as to inflammatory and autoimmune diseases [171].

A clinical investigation of 284 PCR-confirmed COVID-19 patients and 100 healthy controls revealed that mannose-binding lectin 2 (MBL2) gene B variant is common in patients with COVID-19 cases compared to the control group because MBL2 gene is related to lower levels of MBL [174]. Changes in mannose-binding lectin (MBL)- associated serine proteases, MASp-1 and/or MASp-2 levels have been related with COVID-19 risk factors such as sex, diabetes, kidney, cardiovascular, cerebrovascular, and chronic obstructive pulmonary disease (COPD), and association of MASPs and COVID-19 comorbidities has been demonstrated by Bumiller-Bini et al. [173]. Human coronaviruses SARS, MERS, and SARS-CoV-2-induced hyperactivation of MASp-2 aggravates lung injury, and this hyperactivation of MASp-2 is caused through a direct interaction between MASp-2 and coronavirus nucleocapsid protein [175].

Moreover, mannose-binding lectins induce complement cascade, which is a defense against invading pathogens in mucosal immunity [176] and trigger the production of pro-inflammatory cytokines [177]. The complement pathway in SARS-CoV-2 infection has been mentioned as having a “double-edged sword”; it can control mild or asymptomatic cases in COVID-19, but exacerbate local and systemic damage in severe COVID-19 [178]. Complement pathways in SARS-CoV-2 infection has been demonstrated by Bumiller-Bini et al. [173] and shown in Fig. 3.

However, in COVID-19 therapeutic strategy, the complement cascade pathway, particularly lectin pathway has received negligible attention [179] due to the complex pattern of immune dysregulation in COVID-19 patients with acute respiratory failure [180]. Since serum MBL has a key role in innate immunity [181], and can inhibit SARS-CoV in-vitro [166] by preventing ACE2 binding with Spike glycoprotein and also enhances phagocytosis function as an opsonin [182], thus MBPLs may offer potent and alternative biotherapeutic and bioprophylactic strategy against SARS-CoV-2 infections. The following Fig. 4 demonstrates potential role of mannose-binding lectins in prevention of SARS-CoV-2.

### 2.3. Glycosylation for the SARS-CoV-2 antiviral therapeutics and vaccines design

Glycosylation is a ubiquitous post-translational modification of proteins that plays significant roles both in the virus life cycle for stability, antigenicity and infectivity, and in glycos of the host cell receptors for the attachment and entry of the virus [183]. N-glycosylation or N-acetylgalactosamine (GalNAc) and O-glycosylation or N-acetylgalactosamine (GalNAc) are mainly two types of glycosylation sites [185]. Lectins can be used as microarray for high-throughput glycosylation analysis that can aid to screen glycan patterns of therapeutics.
Fig. 2. “Diagram of SARS-CoV-2 entry into host cells. S protein binding to ACE2 receptor and virus attachment to the cell; S protein cleaved by TMPRSS2 produces S1 and S2 subunits. HR1 and HR2 of the S2 subunit gradually approach each other and form a six-helix bundle (6-HB), which causes the virus envelope and host cell membrane to complete fusion.” Adapted from Zhang et al. [156] with permission.

Fig. 3. “Complement pathways in SARS-CoV-2 infection. The activation of the classical pathway occurs through the C1 complex, after recognition of antibodies complexed to SARS-CoV-2. This leads to the cleavage of the C2 component into C2a and C2b. C2a joins the common pathway of the three complement pathways to form the C3 convertase. After binding of MBL/MAF complexes to the surface of pathogens, MASP-1 autoactivates, transactivates MASP-2, and C2 and C4 components are cleaved (C2 and C4 by MASP-2 and C2 by MASP-1), generating the C3 convertase. The alternative pathway is initiated by the spontaneous hydrolysis of component C3, generating C3a and C3b. C3b binds to factor B and is cleaved by factor D, forming the C3 convertase of the alternative pathway. After this step, the three pathways converge into a single pathway. The C3 convertase enzyme cleaves component C3 into C3a and C3b. C3a and C4a are anaphylatoxins that contribute to an increase in inflammatory processes and to the chemotaxis of neutrophils and macrophages (red arrows), while C3b performs viral opsonization. The formation of C5 convertase occurs in different ways through the three pathways, but all generate C5a and C5b. C5a is an anaphylatoxin (as also C3a) that contributes to inflammatory processes, and regulates innate and adaptive immune responses [172], while C5b joins the last C6-C9 components of the cascade and forms the membrane attack complex.” (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Adapted from Bumiller-Bini et al. [173] with permission, and some modifications in the text body.
glycoproteins [184,185]. Viral pathogens use glycans and lectins for the replication and spread, but recent advances in glycobiological research showed that specific glycan-lectin interactions on the basis of viral infectivity and antiviral immunity, can be useful in antiviral strategy [131].

Numerous studies have been performed on Lectins as antimicrobial agents and virucidal agents against several enveloped viruses [186] considering glycan-lectin interactions in antiviral strategies [131]. Besides the ones mentioned before, anti-viral lectins have been isolated from various plants like Scilla campanulata, Narcissus pseudonarcissus, Galanthus nivalis, Polygonatum cyrtonema, as reviewed by Mitchell et al. [12].

Lectins have been used in immunotherapeutic studies for potential prophylactic and therapeutic strategies against microbial infectious diseases, especially plant lectins [187,188]. Lectins from mushroom [189,190], and sea mussel [191] have also been demonstrated to exhibit immunomodulatory activities. Since lectins have exhibited immunomodulatory properties, they can also be used as vaccine bio-adjuvants to improve the efficacy of immunization [192], which has been demonstrated in the laboratory against enveloped viruses such as influenza, hepatitis, and herpes virus, for example see Table 5.

Lectins are potential biomolecules that can induce IL-12, IFN-γ, and T helper type 1 (Th1) protective immunity against viral infections and can also modulate the expression of toll-like receptors (TLRs) which initiate the early immune recognition of the pathogens and the release of proinflammatory cytokines [193]. Current reports strongly suggest that glycobiological and/or “glycovirological” contribution, particularly in glycan-lectin interactions can help for highly effective COVID-19 vaccines and drugs development [131,132] and focusing on glycosylation of Spike glycoprotein can be a novel strategy in the development of both anti-viral vaccine and anti-viral drugs designs against SARS-CoV-2 [157, 183,194].

Table 5

| Name of Lectin [source] | Specificity | Administration route in mice | Vaccine category against viruses |
|------------------------|-------------|------------------------------|--------------------------------|
| AAL [Agrocybe aegerita (V. Brig.) Singer] | N-acetylglucosamine | subcutaneous injection | Inactivated vaccine for H9N2 virus |
| POL [Pleurotus ostreatus (Jacq.) P. Kumm.] | N-acetylgalactosamine | Intramuscular injection | DNA vaccine for Hepatitis B virus |
| KML-C [Viscum album coloratum (Kom.) Nakai] | Galactose/N-acetylgalactosamine | Intranasal route | Inactivated vaccine for H1N1 virus |
| MLI, MLII, MLIII [Viscum album L.] | Galactose/N-acetylgalactosamine | Intranasal route | Subunit vaccine for Herpes simplex virus |

Modified from Nascimento da Silva et al. [193].

Fig. 4. “MBL binding and complement activation enhances phagocytosis by acting as an opsonin.” Adapted from Lau [206] with permission.
3. Concluding remarks

The idea of Lectin-based specific drug delivery was first reported in 1988 via the use of tomato lectin (TL) to target the luminal surface of the small intestine [4]. The lectin-based drug targeting system can be attained via two mechanisms: (i) direct lectin targeting system, which includes carbohydrate molecules that are recognized by endogenous cell surface lectins, and (ii) reverse lectin targeting system, which include exogenous lectins that recognize synthesized carbohydrate molecules on glycolipids and glycoproteins [4,195–197]. Ribosome inactivating lectins (Ulex europeus I and Wheat Germ Agglutinin) containing HIV peptides, hepatitis B surface antigen, TL receptor were used as bioactive molecules for drug targeting as excipients in vaccine application [198]. Antiviral lectins are potential microbicidal molecules for their exhibition of lower toxicity than any other currently used antiviral therapeutics, best for topical applications, odorless, resistant to low pH and high temperatures [143]. Furthermore, rigorous characterization and identification of glycosylation motifs in viral glycoproteins are essential to the design of vaccines and anti-viral drugs [199].

COVID-19 is an infectious disease caused by the zoonotic virus SARS-CoV-2, which has created catastrophe among Homo sapiens worldwide. Scientists and health experts are still working to find out effective therapeutics and vaccines that can eradicate COVID-19. To date, there are six WHO-recognized experimental vaccines available but their efficacy is still under consideration due to continuous SARS-CoV-2 mutations and wane of immunity over time. Bangladesh has also joined the global COVID-19 vaccine race with developing an mRNA-based vaccine candidate [200] with hopes for human trials in November 2021 after completion of successful clinical trials that is happening on non-human primates and monkeys [201].

Numerous attempts have been made with the hope of glycans-based effective antiviral molecules for preventing 2019-nCoV infections. According to our information obtained from established databases, mannose-binding lectins (MBL) have been found to be highly effective against coronaviruses, and mannose-binding plant lectins should have significance for its potent antiviral properties particularly against SARS-CoV-2 as MBL has properties of anti-infectivity, immunoadjuvant, DC-SIGN antagonist, or glycomimetic approach, and specially MBL induces complement cascade pathway, which is a first-line host defense, but MBL has been given limited attention in the COVID-19 biotherapeutic and bioprophylactic strategy. Moreover, decreased levels of serum MBL is a susceptible factor for severe COVID-19 infections and MBL levels in COVID-19 patients should be diagnosed to avoid greater risk of re-infection and disease severity.

Nonetheless, researchers are working hard on plant-based COVID-19 vaccine development via glycoengineering technology and plant-based vaccines have low cost production, rapidity, scalability, and safety [202]. The pharmacological properties and stability, solubility, bioavailability, pharmacokinetics, and immunogenicity of glycosylated biotherapeutics can be determined by the glyco-biotechnological approach, which can propel scientific research to the development of the next generation of biotherapeutics and glycoengineered vaccines [203]. In addition, antiviral lectins for COVID-19 may suffer from low sale production, high cost purification and manufacturing process that can be resolved by the applications of plant biotechnology, as for example molecular farming or transient expression of Griffithsin and Cyanovirin-N in plants [204] as well as Griffithsin (GRFT) in engineered Escherichia coli [205].

To be a consideration, “glycovirology” is an emerging discipline covering both glycobiology and virology, and Bangladesh is a resource of anti-viral medicinal plants with lectins. Altogether, deeper insights into “glycovirological” aspects, antiviral lectins, and glyco-biotechnology may lead to developing highly effective next-generation antiviral biotherapeutic and bioprophylactic against the 21st century’s biological pandemic of SARS-CoV-2 causing COVID-19 and quite possibly other new emerging viruses.

4. Methodological approach in literature search

The authors have performed translating mind derived research questions to keywords in pursuit of specific evidence-based literature to accumulate further information on antiviral lectins against COVID-19. The literature search was performed in PubMed, Google Scholar, Google Search databases by randomly using below keywords: (lectins and coronavirus; lectins and SARS-CoV; medicinal plants and antiviral activity; antiviral plan lectins; molecular mechanisms of actions of antiviral lectins; bioactive compounds and SARS-coronavirus; glycans-lectin interactions for antiviral therapy; glycan and lectins interplay; classifications of lectins; etc.).

The articles were screened and included for this review are proof of concept studies that paid attention to the involvement of inhibitory activity of lectins against SARS-CoV, the antiviral mechanisms of actions of lectins, and studies related to antiviral plant lectins. Furthermore, we also focused on all the relevant articles that were investigated lectins for the antiviral activity. Finally, this review deals with the literature discussion on the potential role of glycosylation for the designing of biotherapeutics and vaccines against SARS-CoV-2.

Funding

This study has received no external or internal funding.

CRedIT authorship contribution statement

Md. Nasir Ahmed: Conceptualization, Visualization, Writing – original draft. Rownak Jahan: Validation, Writing – review & editing. Veeranoot Nissapatorn: Writing – review & editing. Polrat Wilairatana: Funding acquisition. Mohammed Rahmatullah: Supervision, Validation, Writing – review & editing.

Conflict of interest statement

The authors declare have no conflict of interest.

Data availability

No data was used for the research described in the article.

Acknowledgments

This study received no funding. Authors are grateful to scientists and experts worldwide who have contributed to the lectin and glycobiology research.

References

[1] I. Lagardas-Diaz, A.M. Guzman-Partida, L. Vazquez-Moreno, Legume lectins: proteins with diverse applications, J. Mol. Sci. 18 (6) (2017) 1242, https://doi.org/10.3390/jms18061242.

[2] E.J.M. Van Damme, History of plant lectin research, inc. J. Hirabayashi (Ed.), Lectins: Methods and Protocols, Methods in Molecular Biology, 1200, Humana Press, New York, NY, 2014, pp. 3–13, https://doi.org/10.1007/978-1-4939-1292-6_1.

[3] N. Sharon, H. Lis, History of lectins: from hemagglutinins to biological recognition molecules, Glycobiology 14 (11) (2004) 53R, https://doi.org/10.1093/glycob/cwh122.

[4] C. Bies, C.M. Lehr, J.F. Woodley, Lectin-mediated drug targeting: history and applications, Adv. Drug Deliv. Rev. 56 (4) (2004) 425–435, https://doi.org/10.1016/j.addr.2003.10.030.

[5] S.R. Kabir, I. Hasan, A. Zubair, Lectins from medicinal plants: characterizations and biological properties, inc. J.N. Govil (Ed.), Recent Progress in Medicinal Plants-Nutraceuticals and Functional Foods 42, Studium Press LLC, Houton, Texas, USA, 2014, pp. 339–356.

[6] A.G. Ingale, A.U. Hivrale, Plant as a plenteous reserve of lectin, Plant Signal Behav. 8 (12) (2013), e26595, https://doi.org/10.4161/psb.26595.

[7] R. Moreira, I.L. Ainoz, J.T. De Oliveira, B.S. Cavada, Plant lectins, chemical and biological aspects, Mem. Inst. Oswaldo Cruz 86 (2) (1991) 211–218, https://doi.org/10.1590/s0074-02761991000600048.
[29] D. Khadka, M.K. Dhamala, F. Li, P.C. Aryal, R.B. O’Keefe, Antiviral activity of a novel banana lectin, Sci. Rep. 7 (2017) 4342, https://doi.org/10.1038/s41598-017-04342-z.

[30] B. Patel, S. Sharma, N. Nair, J. Majeed, R.K. Goyal, M. Dhobi, Therapeutic potential of a medicinal plant from Ethiopia: a review of plants traditionally used to treat viral diseases, Evid. Based Complement Altern. Med. 2021 (2021) 10624110, https://doi.org/10.1155/2021/10624110.

[31] G. de Sousa Ferreira Soares, A.M. Assrey, C.A. de Almeida Gadelha, V. de Almeida, S.T. Gadelha, Leguminosae lectins as biological tools in medical research: a review, Braz. Arch. Biol. Technol. 64 (2021), e21200170, https://doi.org/10.1590/1678-4324-2021200170.

[32] G. de Sousa Ferreira Soares, A.M. Assrey, C.A. de Almeida Gadelha, V. de Almeida, S.T. Gadelha, Leguminosae lectins as biological tools in medical research: a review, Braz. Arch. Biol. Technol. 64 (2021), e21200170, https://doi.org/10.1590/1678-4324-2021200170.

[33] S.K. Lam, T.B. Ng, Lectins: production and practical applications, Appl. Microbiol. Biotechnol. 89 (1) (2014) 321–331, https://doi.org/10.1007/s00253-013-5105-2.

[34] O.A. Adeleye, M.N. Femi-Oyewo, A.O. Bamire, L.G. Bakre, A. Alabi, J.S. Ashidi, A.A. Balogun-Agbaje, O.A. Aromokun, M.A. Hassan, F. Gafoka, Ethnomedical herbs in African traditional medicine with potential activity for the prevention, treatment, and management of coronavirus disease 2019, Future. J. Pharm. Sci. 1 (2021), 72, https://doi.org/10.4172/2381-073X-1000123.

[35] S.B. Raja, M.R. Murali, N.K. Kumar, S.N. Devraj, Isolation and partial characterisation of a novel lectin from Aegle marmelos fruit and its effect on adherence and invasion of Shigella to HT29 Cells, PLoS One 6 (1) (2011), e16231, https://doi.org/10.1371/journal.pone.0016231.

[36] I. Badam, S.S. Bedekar, B.K. Sonavane, S.P. Jondhle, In vitro antiviral activity of Red (Aegle marmelos Corr) upon human coxsackieviruses B1–B6, J. Commun. Dis. 34 (3) (2002) 88–99.

[37] C. Barton, J.C. Kouokam, A.B. Lasnik, O. Foreman, A. Cambon, G. Brock, D. M. Mazalovska, J.C. Kouokam, Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections, BioMed. Res. Int. (2018) 3750646, https://doi.org/10.1155/2018/3750646.

[38] B. Shao, S. Wang, J. Zhou, L. Ke, P. Rao, A novel lectin from fresh rhizome of Alnus incana (samar) Juzep., Process Biochem. 46 (2011) 1554–1559, https://doi.org/10.1016/j.procbio.2011.04.010.

[39] Z.Y. Jiang, X.M. Zhang, F.X. Zhang, N. Liu, F. Zhao, J. Zhou, J.J. Chen, A new triterpene and anti-hepatitis B virus active compounds from Alisma orientalis, Planta Med. 72 (10) (2006) 951–954, https://doi.org/10.1055/s-2006-947178.

[40] B. Montefiori, C. Barton, J.C. Kouokam, A.B. Lasnik, O. Foreman, A. Cambon, G. Brock, D. M. Mazalovska, J.C. Kouokam, Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections, BioMed. Res. Int. (2018) 3750646, https://doi.org/10.1155/2018/3750646.

[41] M.D. Swanson, D.M. Boudreaux, L. Salmon, J. Chugh, H.C. Winter, J.L. Meagher, D. Huskens, K. Vermeire, E. Vandemeulebroucke, J. Balzarini, D. Schols, Safety and effect of subcutaneous treatment with the broad-spectrum antiviral lectin BIRD GW, ANTI-T, J. Biol. Chem. 296 (2021) 100698, https://doi.org/10.1016/j.jbc.2021.100698.

[42] M. Mazalovska, J.C. Kouokam, Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections, BioMed. Res. Int. (2018) 3750646, https://doi.org/10.1155/2018/3750646.

[43] M. D. Swanson, D. M. Boudreaux, L. Salmon, J. Chugh, H. C. Winter, J. L. Meagher, D. Huskens, K. Vermeire, E. Vandemeulebroucke, J. Balzarini, D. Schols, Safety and effect of subcutaneous treatment with the broad-spectrum antiviral lectin BIRD GW, ANTI-T, J. Biol. Chem. 296 (2021) 100698, https://doi.org/10.1016/j.jbc.2021.100698.

[44] S. Oh, D. Kim, Development of lectin-linked immunomagnetic separation for the detection of hepatitis A virus, Viruses 6 (3) (2014) 1037, https://doi.org/10.3390/v60301037.

[45] C. Barton, J.C. Kouokam, A.B. Lasnik, O. Foreman, A. Cambon, G. Brock, D. M. Mazalovska, J.C. Kouokam, Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections, BioMed. Res. Int. (2018) 3750646, https://doi.org/10.1155/2018/3750646.

[46] K. Shimotohno, Screening of various plant extracts used in ayurvedic medicine for inhibitory effects on human immunodeficiency virus type 1 (HIV-1) protease, Phytother. Res. 9 (1995) 180–184, https://doi.org/10.1002/ptr.28009_18.

[47] J.F. Dixon, P. Keefe, Antiviral lectins: selective inhibitors of viral entry, Antivir. Res. 142 (2017) 37–54, https://doi.org/10.1016/j.antiviral.2017.03.007.

[48] D. Huskens, K. Vermeire, C. Barton, A. Hertoghe, D. Schols, Safety and effect of subcutaneous treatment with the broad-spectrum antiviral lectin BIRD GW, ANTI-T, J. Biol. Chem. 296 (2021) 100698, https://doi.org/10.1016/j.jbc.2021.100698.

[49] B. Shao, S. Wang, J. Zhou, L. Ke, P. Rao, A novel lectin from fresh rhizome of Alnus incana (samar) Juzep., Process Biochem. 46 (2011) 1554–1559, https://doi.org/10.1016/j.procbio.2011.04.010.

[50] Y.S. Chan, T.B. Ng, Lectins as promising therapeutics for the prevention and treatment of HIV and other potential coinfections, BioMed. Res. Int. (2018) 3750646, https://doi.org/10.1155/2018/3750646.
glycosylation and binding of lipids, Int. J. Biol. Macromol. 72 (2015) 1376–1383, https://doi.org/10.1016/j.ijbiomac.2015.04.006.

[55] K.Y. Hirnath, P. Hegde, M. Sharma, S.R. Inamdar, A modified method for purification of N-acetylgalactosamine specific lectin from Butea monosperma seeds and its effect on human hepatocellular carcinoma cell growth, J. Plant Biochem. Biotechnol. 28 (2019) 397–404, https://doi.org/10.15621/jpbi.2019.01.004819.

[56] R.N. Yadava, L. Thiyagarajan, A potential antiviral flavone glycoside from the seeds of Butea monosperma O. Kuntze, J. Asian Nat. Prod. Res. 7 (2005) 185–188, https://doi.org/10.1080/14786410500204054.

[57] A. Naesem, R.H. Khan, H. Vikram, M. Akif, Purification of Cajanus cajan root lectin and its interaction with Hisibial lipopolysaccharide as studied by different spectrocopstic techniques, Arch. Biochem. Biophys. 396 (1) (2001) 99–105, https://doi.org/10.1006/abbi.2001.2595.

[58] U.W. Nwodo, A.U. Urogbo, O.A. Onyedikachi, V.N. Chigor, A.I. Okoh, In vivo evaluation of the antiviral activity of Cajanus cajan on measles virus, Arch. Virol. 156 (9) (2011) 1551–1557, https://doi.org/10.1007/s00705-011-1032-x.

[59] M.A. Ali, M.A. Sayered, N. Absar, Purification and characterization of three lectins extracted from Cassia fistula seeds and effect of various physical and chemical agents on their stability, J. Chin. Chem. Soc. 51 (2004) 647–654, https://doi.org/10.1002/jccs.200400097.

[60] S. Anubhuti, L. Vijay, G. Anjana, S. Viney, B. AK Anti-viral activity of Cassia fistula extract and its bioactivity on different plant lectins, Int. J. Biol. Macromol. 110 (2018) 588–597, https://doi.org/10.1016/j.ijbiomac.2018.01.058.

[61] S. Vimalanathan, S. Ignacimuthu, J.B. Hudson, Medicinal plants of Tamil Nadu (Southern India) are a rich source of antiviral activities, Pharm. Biol. 47 (5) (2009) 422–429, https://doi.org/10.1080/13880200902918196.

[62] K.B. Bobbili, D. Datta, S. Mondal, S. Polepalli, G. Poblenz, M. Morrow, M. J. Sweeney, Purification of plant lectin agglutinins and their properties and functional role in the stability of CA2A, a new PP2A like phloem exudate lectin from ivy gourd (Coccinia indica), Int. J. Biol. Macromol. 110 (2018) 588–597, https://doi.org/10.1016/j.ijbiomac.2018.01.051.

[63] A.H. Arbab, M. Iqbal, M.S. Al-Donasi, A.J. Al-Rehaily, In vitro evaluation of novel antiviral activities of 60 medicinal plants extracts against hepatitis B virus, Exp. Ther. Med. 14 (1) (2017) 626–634, https://doi.org/10.3892/etm.2017.4530.

[64] M.M.H. Khan, A.T.M.M. Rahman, M.S. Uddin, S. Khatun, F. Pervin, N. Absar, Purification and characterization of lectins from jute (Corchorus olitorius) leaves, J. Chin. Chem. Soc. 55 (2008) 1171–1177, https://doi.org/10.1002/jccs.200800019.

[65] H. Hasan, E.J. Kadhim, Phytochemical investigation of Corchorus olitorius L. leaves cultivated in Iraq and its in vitro antiviral activity, Iraqi J. Pharm. Sci. 27 (2) (2018) 115–122, https://doi.org/10.13153/vol27i2p115-122.

[66] S.K. Sarkar, M.T. Hosain, M.B. Uddin, N. Absar, Purification, characterization and physico-chemical properties of three galactose-specific lectins from pumpkin (Cucurbita maxima) seed kernels, J. Chin. Chem. Soc. 54 (2007) 1433–1442, https://doi.org/10.1002/jccs.200700203.

[67] K. Nishimoto, K. Tanaka, T. Murakami, H. Nakashita, H. Sakamoto, S. Oguri, Datura stramonium agglutinin: cloning, molecular characterization and recombinant production in Arabidopsis thaliana, Glycobiology 25 (2015) 157–169, https://doi.org/10.1093/glycobiology/giv098.

[68] S. Mioraj, Datura stramonium: an updated review, Der Pharm. Chem. 8 (17) (2016) 253–257.

[69] T.K. Datta, P.S. Basu, Identification, isolation and some properties of lectins from the seeds of Indian coral tree [Erythrina variegata (Linn.) var. orientalis (Linn.) Merrill], Biochem. Biophys. Acta 193 (1969) 751–757.

[70] Y. Namasaki, M. Kimura, O. Yamaguchi, M. Araki, Isolation and characterization of isolectins from Erythrina variegata seeds, J. Chromatogr. A 597 (1)–(2) (1992) 207–211.

[71] A. Makhloof, S.A. Al-Sohaimy, Y. Mouostaif, M. Saadani, H. Makhloof, A.N. D. ISOLATION, IDENTIFICATION OF LECTIN GENE IN LICO- RICE, Glycorrhiza glabra L., PLANT IN EGYPT, Egypt J. Genet. Cytol. 42 (2013) 183–193.

[72] J. Cinati, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, H.W. Doerr, Glycyrrhizin, an active component of liquorice roots, and replication of SARS-coronavirus, Lancet 361 (9347) (2003) 2045–2046, https://doi.org/10.1016/S0140-6736(03)16315-x.

[73] C. Fiore, M. Eisenbud, R. Krause, E. Ragazzi, D. Pellati, D. Armanini, J. Birdenberg, Antiviral Effects of Glycyrrhizin on the Host Cell, Phythother. Res. 22 (2) (2008) 141–146, https://doi.org/10.1002/ptr.2295.

[74] S.R. Kahir, A. Hosn, A. Zubair, J. Alom, F. Islam, A. Hossain, Y. Kimura, A new lectin from the tuberous rhizome of Amsonia rotundifolia: isolation, characterization, antifungal and antiproliferative potential, Proteins Pept. Lett. 18 (11) (2011) 1140–1149, https://doi.org/10.2174/187296861797208896.

[75] A.Zamn, A. Aturr, S. Ariangrung, R. Nureetti S. isolation, identification and antiviral activity of bioactive compounds of Kaempferia rotundare, in: 3rd International Conference on Chemistry and Chemical Engineering, IPCEEE, 2012, pp. 27–30. 12. IACSIT Press, Singapore.

[76] W. Konkurnnerd, A. Kanchanrat, P. Sangvichan, A thermostable lectin from the rhizomes of Kaempferia parviflora, J. Sci. Food Agric. 90 (11) (2010) 1920–1925, https://doi.org/10.1002/ps.20403.

[77] K. Sookkongware, M. Geitmann, S. Roengsumran, A. Petsom, U.H. Danielson, Inhibition of viral protein synthesis by Zingerberaceous extracts and flavones isolated from Kaempferia parviflora, Die Pharm. 61 (8) (2006) 717–721.
Biomedicine & Pharmacotherapy 146 (2022) 112507

13

[192] H.R. Reyna-Margarita, C.M. Irais, R.G. Mario-Alberto, R.M. Agustina, S.G. Luis-Benjamin, P.E. David, Plant phenolics and lectins as vaccine adjuvants, Curr. Pharm. Biotechnol. (2019) 20, https://doi.org/10.2174/138921020666190716110705.

[193] L.C. Nascimento da Silva, J. Mendonça, W.F. de Oliveira, K. Batista, A. Zagmignan, I. Viana, M.T. Dos Santos Correia, Exploring lectin-glycan interactions to combat COVID-19: lessons acquired from other enveloped viruses, Glycobiology 31 (4) (2021) 358–371, https://doi.org/10.1093/glycob/cwa099.

[194] C.A. Reis, R. Tauber, V. Blanchard, Glycosylation is a key in SARS-CoV-2 infection, J. Mol. Med. 99 (8) (2021) 1023–1031, https://doi.org/10.1007/s00109-020-02092-0.

[195] T. Minko, Drug targeting to the colon with lectins and neoglycoconjugates, Adv. Drug Deliv. Rev. 56 (4) (2004) 491–509, https://doi.org/10.1016/j.addr.2003.10.017.

[196] A. Rek, E. Krenn, A.J. Kungl, Therapeutically targeting protein-glycan interactions, Br. J. Pharmacol. 157 (5) (2009) 686–694, https://doi.org/10.1111/j.1476-5381.2009.00226.x.

[197] V.E. Plattner, G. Ratzinger, E.T. Engleder, S. Gallauner, F. Gabor, M. Wirth, Alteration of the glycosylation pattern of monocytic THP-1 cells upon differentiation and its impact on lectin-mediated drug delivery, Eur. J. Pharm. Biopharm. 73 (3) (2009) 324–330, https://doi.org/10.1016/j.ejpb.2009.07.004.

[198] L.I. de Juan, V.G. Recio, P.J. López, T.G. Juan, M. Cordoba-Díaz, D. Cordoba-Díaz, Pharmaceutical applications of lectins, J. Drug Deliv. Sci. Technol. 42 (2017) 126–133, https://doi.org/10.1016/j.jddst.2017.05.018.

[199] I. Bagdonaite, S.Y. Vakhrushev, H.J. Joshi, H.H. Wandall, Viral glycoproteomes: technologies for characterization and outlook for vaccine design, FEBS Lett. 592 (23) (2018) 3898–3920, https://doi.org/10.1002/1873-3468.13177.

[200] K. Nag, J. Chandra Baray, M. Rahman Khan, A. Mahmud, J. Islam, S. Myti, R. Ali, E.H. Sarker, S. Kumar, M.H. Chowdhury, R. Roy, F. Islam, U. Barman, H. Khan, S. Chakraborty, A. Baddha, M. Hossain, S. ahmmad, M.R. Chowdhury, P. Ghosh, R.I. Shimul, R. Ahmmed, E.H. Bhuiya, B.K. Biswas, M.M. Moliuddin, N. Sultana, An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immune response with single dose, Vaccine 39 (28) (2021) 3745–3755, https://doi.org/10.1016/j.vaccine.2021.05.015.

[201] Antara, AF. Globe Biotech hopes for Bangavax human trials in September, 2021. (https://www.dhakatribune.com/bangladesh/2021/08/13/globe-biotech-hopes-for-bangavax-human-trials-september) (Accessed 8 September 2021).

[202] P.M. Maharjan, S. Choe, Plant-based COVID-19 vaccines: current status, design, and development strategies of candidate vaccines, Vaccines 9 (9) (2021) 992, https://doi.org/10.3390/vaccines9090992.

[203] K. Alagesan, M. Hoffmann, E. Rapp, D. Kolarich, Glycoproteomics technologies in glycobiotechnology, Adv. Biochem. Eng. Biotechnol. 175 (2021) 413–434, https://doi.org/10.1007/10.2020.144.

[204] T. Capell, R.M. Twyman, V. Armario-Najera, J.K. Ma, S. Schillberg, P. Christou, Potential applications of plant biotechnology against SARS-CoV-2, Trends Plant Sci. 25 (7) (2020) 635–643, https://doi.org/10.1016/j.tplants.2020.04.009.

[205] J.S. Decker, R. Menacho-Melgar, M.D. Lynch, Low-cost, large-scale production of the anti-viral lectin griffithsin, Front. Bioeng. Biotechnol. 8 (2020) 1020, https://doi.org/10.3389/fbioe.2020.01020.

[206] K.K. Lu, Reducing COVID-19 risk through dietary supplementation of plant mannose binding lectins, Int. J. Corona 1 (4) (2020) 4–11, https://doi.org/10.14302/issn.2692-1537.jcv-20-3492.